| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 03/18/2004 | US20040053981 Such as 2-(5(6)-nitro-2-benzimidazoyl)-5-(4-nitrophenyl)furan; fluorescent quantitative analysis; for treatment/prevention of cancer |
| 03/18/2004 | US20040053973 Substituted 1,3-thiazole compounds, their production and use |
| 03/18/2004 | US20040053971 A fluorinated compounds, microbiocides, synthesis with chemical intermediates, amidation, debromination, benzylation, oximination |
| 03/18/2004 | US20040053955 An immunosuppressants for treating allograft rejection, transplant rejection, psoriasis, and rheumatoid arthritis, a 9,10-dihydro-9-oxo-acridine-3-yl- derivatives |
| 03/18/2004 | US20040053954 Treating bacterial infections with a 1,2,3,4-tetrahydrobeta-carbolin-2-yl-alkyl-1-one; chemical intermediates, amidation |
| 03/18/2004 | US20040053953 Treatment of chemokine mediated diseases |
| 03/18/2004 | US20040053942 Fused pyrazole derivatives bieng protein kinase inhibitors |
| 03/18/2004 | US20040053941 Substituted pyrazine derivatives |
| 03/18/2004 | US20040053937 Pyrimidine compounds |
| 03/18/2004 | US20040053936 Medicinal composition for oral use |
| 03/18/2004 | US20040053932 Peptide deformylase inhibtors |
| 03/18/2004 | US20040053928 Quinoline derivatives as antibacterials |
| 03/18/2004 | US20040053925 Novel urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and novel use |
| 03/18/2004 | US20040053920 Administering to a patient suffering from caspase mediated diseses, an effective amount of a mono,bi or tri-heterocyclic ring containing nitrogen atom attached to ester or thioester to form carbamate group, as caspase inhibitor |
| 03/18/2004 | US20040053875 Comprises double-stranded RNA; extracted from HeLa cells |
| 03/18/2004 | US20040053873 Electroporation methods for introducing bioactive agents into cells |
| 03/18/2004 | US20040053872 Administering polynucletides that inhibit interactions polymerases with tRNA, to humans for prophylaxis of aquired immune deficiency syndrome |
| 03/18/2004 | US20040053862 Macrolide solvates |
| 03/18/2004 | US20040053858 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract |
| 03/18/2004 | US20040053851 Association of calpain inhibitors and reactive oxygen species trapping agents |
| 03/18/2004 | US20040053847 Suitable for treatment of cancer and for treatment, particularly topical treatment, of infections caused by pathogenic organisms such as bacteria and fungi |
| 03/18/2004 | US20040053845 Modified peptides as therapeutic agents |
| 03/18/2004 | US20040053833 Relates to regulation of activity of NET (ERP/SAP-2) protein and to compounds which modify or regulate NET protein activity; methods of screening for agonists or antagonists of NET in order to identify new pro- or anti-angiogenic compounds |
| 03/18/2004 | US20040053828 Partial peptide mimetics and methods |
| 03/18/2004 | US20040053815 Inactivating a nuclear localization signal of a protein by contacting the protein with a compound that binds reversibly; parasiticides; viricides |
| 03/18/2004 | US20040053393 Comprises genetically engineered bacteriophage polymerase for detection and treatment of microorganismal infections |
| 03/18/2004 | US20040053316 Contacting composition with an aziridine derivative inactivating agent; killed virus-containing vaccines |
| 03/18/2004 | US20040053281 Comprises enzymatic polypeptide associated with fatty acid metabolism for diagnosing, treating and preventing cancer, neurodegenerative, autoimmune/inflammatory, gastrointestinal and cardiovascular disorders |
| 03/18/2004 | US20040053220 Replication assay for detecting anti-viral substances |
| 03/18/2004 | US20040052873 Bioavailability / bioefficacy enhancing activity of cuminum cyminum and extracts and fractions thereof |
| 03/18/2004 | US20040052870 Cyclooxygenase (COX-2) inhibitors; for treatment/prevention of inflammation; nutraceuticals; for treatment of nervous system disorders |
| 03/18/2004 | US20040052866 Administering gaseous carbon monoxide; also for treatment of alcoholism |
| 03/18/2004 | US20040052841 Pharmaceutical preparation with retarding active ingredient release, method for its production and its use |
| 03/18/2004 | US20040052820 Peptide containing amino acids 638 to 673 of the HIV-1LAI gp41 protein, and fragments, analogs and homologs of DP178, inhibitory of human and nonhuman retroviral, especially HIV, transmission to uninfected cells |
| 03/18/2004 | US20040052818 Flavivirus mutant has a deletion in the capsid protein of at least more than 4 successive amino acids, wherein the carboxy terminal hydrophobic region is not affected by the deletion |
| 03/18/2004 | US20040052816 Recombinant protective protein from streptococcus pneumoniale |
| 03/18/2004 | US20040052813 Polypeptide fragments of hepatitis e virus, the vaccine composition comprising said fragments and the diagnostic kits and the diagnostic kits |
| 03/18/2004 | US20040052812 Immunogenic complex containing a multi-component viral particle covalently linked to a javelin molecule, wherein the javelin molecule is a peptide which selectively binds to a heat shock protein |
| 03/18/2004 | US20040052802 Attenuated mutant; prevent inferctions, diarrhea; human and veterinary medicine |
| 03/18/2004 | US20040052789 Novel proteins genes encoding them and method of using the same |
| 03/18/2004 | US20040052781 Vaccine compositions comprising Streptococcus pneumoniae polypeptides having selected structural motifs |
| 03/18/2004 | US20040052779 Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria |
| 03/18/2004 | US20040052775 Antigens; induce immunology response; prevent infections; genetic engineering |
| 03/18/2004 | US20040052769 Methods of utilizing cultured non-gvhd inducing t lymphocytes to treat disease |
| 03/18/2004 | US20040052729 Immobilization carbohydrates; calibration; diagnosis; antiinflammatory agents, bactericides |
| 03/18/2004 | DE10241407A1 Behandlung nicht allergischer Rhinitis durch selektive Phosphodiesterase 4-Hemmstoffe Treatment not allergic rhinitis by selective phosphodiesterase 4 inhibitors |
| 03/18/2004 | DE10130985B4 Verfahren zur Diagnose von Sepsis und schweren Infektionen unter Bestimmung löslicher Cytokeratin-1-Fragmente A method for the diagnosis of sepsis and severe infections by determining soluble cytokeratin-1 fragments |
| 03/18/2004 | CA2501924A1 Non-nucleoside reverse transcriptase inhibitors |
| 03/18/2004 | CA2498297A1 Recombinatant mutants of rhabdovirus and methods of use thereof |
| 03/18/2004 | CA2497989A1 Probiotic bacterium: lactobacillus fermentum |
| 03/18/2004 | CA2497972A1 Hbv precore protein having a particle-forming ability |
| 03/18/2004 | CA2497833A1 A method of modulating cellular activity and molecules for use therein |
| 03/18/2004 | CA2497696A1 Increasing the absorption of substances via the skin and mucous membranes |
| 03/18/2004 | CA2497374A1 Treatment of non-allergic rhinitis by means of selective phosphodiesterase-4 inhibitors |
| 03/18/2004 | CA2493974A1 Pharmaceutical dosage form comprising a sulfite compound |
| 03/18/2004 | CA2407301A1 Hsp60 sequence from piscirickettsia salmonis |
| 03/17/2004 | EP1398379A2 Compounds for immunotherapy and diagnosis of tuberculosis |
| 03/17/2004 | EP1398314A1 Carbapenem compound |
| 03/17/2004 | EP1398036A1 Ganoderma lucidum spores for treatment of autoimmune diseases |
| 03/17/2004 | EP1398033A2 Use of benzodiazepines for treating autoimmune diseases, inflammations, neoplasies, viral infections and atherosclerosis |
| 03/17/2004 | EP1398025A1 Fine inorganic particles having drug included therein, method for preparation thereof and pharmaceutical preparation comprising fine inorganic particles having drug included therein |
| 03/17/2004 | EP1397494A2 Fungal gene cluster associated with pathogenesis |
| 03/17/2004 | EP1397489A2 Tissue-specific and pathogen-specific toxic agents, ribozymes, dnazymes and antisense oligonucleotides, and methods of use thereof |
| 03/17/2004 | EP1397384A2 Antimicrobially active peptide |
| 03/17/2004 | EP1397374A2 Siglec inhibitors |
| 03/17/2004 | EP1397364A1 Novel pyrrole derivatives as pharmaceutical agents |
| 03/17/2004 | EP1397363A1 5-ethyl-imidazotriazinones |
| 03/17/2004 | EP1397359A1 1-biaryl-1,8-napthyridin-4-one phosphodiesterase-4 inhibitors |
| 03/17/2004 | EP1397356A1 Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (pai-1) |
| 03/17/2004 | EP1397162A2 Water-soluble antibiotic comprising an amino sugar, in the form of a polysaccharide conjugate |
| 03/17/2004 | EP1397159A2 Stable liquid formulations of antibodies |
| 03/17/2004 | EP1397157A2 Antibacterial agent |
| 03/17/2004 | EP1397154A2 Abin-mediated hepatitis protection |
| 03/17/2004 | EP1397151A2 Wnv core protein/capsid interacting protein and uses of the same |
| 03/17/2004 | EP1397150A2 Somatostatin agonists |
| 03/17/2004 | EP1397137A1 Hydantion derivatives as inhibitors of matrix metalloproteinases |
| 03/17/2004 | EP1397131A1 Compositions comprising nitrofurantoin and uva ursi |
| 03/17/2004 | EP1397105A1 Methods for inhibiting angiogenesis |
| 03/17/2004 | EP1397053A1 Oral composition comprising an extract from the bark of albizzia myriophylla |
| 03/17/2004 | EP1244434B1 Use of chemotherapeutic agents |
| 03/17/2004 | EP1242406B1 Novel compounds |
| 03/17/2004 | EP1242119B1 Combinations for the treatment of dna viral infections comprising a loop diuretic and a cardiac glycoside |
| 03/17/2004 | EP1212072B1 Pharmaceutical composition that contains eucalyptus and orange oil |
| 03/17/2004 | EP1147102B1 Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors |
| 03/17/2004 | EP1140932B1 1,8-benzonaphthyridine derivatives |
| 03/17/2004 | EP1100792B1 Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases |
| 03/17/2004 | EP1097148B1 Polymorph of ritonavir |
| 03/17/2004 | EP0973546B1 Stabilized human papillomavirus formulations |
| 03/17/2004 | EP0948523B1 Peptidomimetic inhibitors of the human cytomegalovirus protease |
| 03/17/2004 | EP0731807B1 N-2 substituted purines |
| 03/17/2004 | CN1483079A Immunoregulation polynucleotide and using method thereof |
| 03/17/2004 | CN1483032A Process for making substituted 8-arylquinolinium benzenesulfonate |
| 03/17/2004 | CN1483031A Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them |
| 03/17/2004 | CN1483026A Benzoylpyridazine |
| 03/17/2004 | CN1483023A 3-arylindole derivatives and their use as cb2 receptor agonists |
| 03/17/2004 | CN1482918A Modulation of smr1-nep interactions in cns disorders giving rise to mental disorders |
| 03/17/2004 | CN1482917A New therapeutic uses of smr1 peptides |
| 03/17/2004 | CN1482914A Remedies for hepatitis c |
| 03/17/2004 | CN1482905A Compositions for oral use |
| 03/17/2004 | CN1482861A Method of sterilizing antibody-containing milk and products containing sterilized antibody-containing milk by filtration to remove bacteria |